Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012

Bio-Medicine.Org

LA JOLLA, Calif., Nov. 3, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (*NASDAQ: RGLS*), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that new preclinical data targeting microRNA-21 (miR-21) will be presented at 10:00 a.m. PDT on November 3, 2012 in a late-breaking poster session at the American Society of Nephrology's Kidney Week 2012, meeting in San Diego, CA, October 30—November 4, 2012.

Late-Breaker Poster Presentation on miR-21 - November 3, 2012 10:00 a.m. PDT

- Anti-miR-21 Protects Collagen IVα(3) Deficient Mice from Progression of Alport Disease-

Regulus scientists and its collaborator, Jeremy Duffield M.D., Ph.D., Associate Professor of Medicine in the Division of Nephrology at the University of Washington, will present data demonstrating that therapeutic oligonucleotides targeting miR-21 (anti-miR-21) reduces the severity of fibrosis and improves renal function in a rodent model of Alport syndrome. Regulus' miR-21 therapeutic development program, which is partnered with Sanofi, is currently in preclinical testing for both kidney fibrosis and hepatocellular carcinoma.

"We are pleased to present at Kidney Week and believe these data further validate that anti-miR-21 is a potential new therapy for human kidney disease," said Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus. "We're making good progress toward the selection of an anti-miR-21 clinical development candidate and are excited about the potential to bring this innovative treatment to patients with fibrotic diseases."

The abstract can be accessed at Regulus' website, http://www.regulusrx.com [1], in the Publications page.

About Regulus

Regulus Therapeutics Inc. (*NASDAQ:RGLS*) is a biopharmaceutical company leading the discovery and development of
'/>"/>

Source URL (retrieved on *05/25/2013 - 8:07am*):
http://www.mdtmag.com/news/2012/11/regulus-presents-new-preclinical-data-

mir-21-kidney-week-2012?qt-recent_content=0

Links:
[1] http://www.regulusrx.com/